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Lymphotoxin-a (LTA) is a pro-inflammatory cytokine that plays an important role in the immune system and local
inflammatory response. LTA is expressed in atherosclerotic plaques and has been implicated in the pathogenesis of
atherosclerosis and coronary heart disease (CHD). Polymorphisms in the gene encoding lymphotoxin-a (LTA) on
Chromosome 6p21 have been associated with susceptibility to CHD, but results in different studies appear to be
conflicting. We examined the association of seven single nucleotide polymorphisms (SNPs) across the LTA gene, and
their related haplotypes, with risk of myocardial infarction (MI) in the International Study of Infarct Survival (ISIS) case-
control study involving 6,928 non-fatal MI cases and 2,712 unrelated controls. The seven SNPs (including the rs909253
and rs1041981 SNPs previously implicated in the risk of CHD) were in strong linkage disequilibrium with each other
and contributed to six common haplotypes. Some of the haplotypes for LTA were associated with higher plasma
concentrations of C-reactive protein (p¼0.004) and lower concentrations of albumin (p¼0.023). However, none of the
SNPs or related haplotypes were significantly associated with risk of MI. The results of the ISIS study were considered
in the context of six previously published studies that had assessed this association, and this meta-analysis found no
significant association with CHD risk using a recessive model and only a modest association using a dominant model
(with narrow confidence intervals around these risk estimates). Overall, these studies provide reliable evidence that
these common polymorphisms for the LTA gene are not strongly associated with susceptibility to coronary disease.
Citation: Clarke R, Xu P, Bennett D, Lewington S, Zondervan K, et al. (2006) Lymphotoxin-a gene and risk of myocardial infarction in 6,928 cases and 2,712 controls in the ISIS
case-control study. PLoS Genet 2(7): e107. DOI: 10.1371/journal.pgen.0020107
Introduction
Lymphotoxin-a (LTA) is a cytokine produced by all cells in
the body in response to tissue injury, and it plays an
important role in regulation of the immune system and local
inﬂammatory response [1]. LTA and tumour necrosis factor
share a common receptor that controls the expression of
vascular endothelial cell adhesion molecules and nitric oxide
production [2]. LTA is expressed in atherosclerotic plaques in
animal models, and has been implicated in the pathogenesis
of atherosclerosis and coronary heart disease (CHD) [3,4].
In an initial genome-wide case-control screen involving
65,671 single nucleotide polymorphisms (SNPs) from 13,738
genes in 94 myocardial infarction (MI) cases and 658 controls
in Japan, susceptibility to MI appeared to be associated with
the SNP 252A!G (rs909253) in the LTA gene, which encodes
LTA on Chromosome 6p21 [5]. This possible association with
rs909253, and with two further SNPs (rs1800683 and
rs1041981) in near-perfect linkage disequilibrium (LD) with
it, was subsequently replicated by the same investigators in a
further 1,133 MI cases and 1,006 controls. Among these SNPs,
the non-synonymous coding SNP rs1041981 seemed to be
most strongly implicated because of its association with
induction of vascular endothelial adhesion molecules [5]. An
association of rs909253 or rs1041981 with the risk of CHD has
subsequently been observed in some smaller studies [6,7], but
not in others [8–10].
If genetic variants associated with the control of pro-
inﬂammatory cytokines are associated even modestly with MI
risk, this could have important implications for under-
standing the pathogenesis of atherosclerosis. However,
reliable conﬁrmation or refutation of such associations
typically requires studies involving much larger numbers of
cases than in the original hypothesis-generating studies
[11,12]. We have examined the association between seven
SNPs in the LTA gene, and their related haplotypes, with risk
of MI in the large ISIS [13] case-control study, and then
included it in a meta-analysis of all previously published
reports on this association.
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Table 1 shows the location and relevant characteristics of
the seven SNPs in the LTA gene on chromosome 6p21 that
were examined in the International Study of Infarct Survival
(ISIS) study. Data for six of these SNPs were available in 6,928
cases and 2,712 controls, and for one SNP (rs1041981) in only
6,858 cases and 2,690 controls who had sufﬁcient DNA. The
mean age was 54.8 y (standard deviation 67.3 y) in cases and
46.2 y (standard deviation 69.6 y) in controls (Table 2). The
MI cases had a higher mean body mass index (BMI) and
higher prevalence of current smokers, hypertension, and
diabetes mellitus compared with controls. Table 2 also shows
that, compared with controls, MI cases had higher plasma
concentrations of apolipoprotein B, ﬁbrinogen, and C-
reactive protein (CRP), and lower mean concentrations of
apolipoprotein A1 and albumin.
LTA SNPs and Haplotypes
All seven SNPs studied in the LTA gene were in Hardy-
Weinberg Equilibrium (HWE) among both cases and controls
(unpublished data). Reproducibility of the genotyping was
high, with a weighted kappa score of 0.99–1.00 for each of
these seven SNPs in the LTA gene (unpublished data). The
region of LTA investigated in our study, which spanned about
1 kb and was bounded by rs2071590 and rs1041981, and
included all three SNPs examined in the study that had
generated the hypothesis of association with CHD [5]. It also
included the rs1041981 SNP examined in the PROCARDIS
and other published studies of the LTA gene and CHD [9,10].
Table 3 shows that all seven SNPs examined were in high LD,
with pair-wise LD measured in terms of D
I   0.85 between
each SNP. Although the pairwise r
2 values between some of
the SNPs were low (perhaps due to differences in allele
frequency), the r
2 values between the rs909253, rs1800683,
and rs1041981 SNPs implicated in the hypothesis-generating
study [5] were  0.98. Hence, all of the SNPs studied were
incorporated in the haplotype analysis.
Associations with CRP, Fibrinogen, and Albumin
Table 4 shows the mean (standard error) values of
cardiovascular risk factors by individual LTA haplotypes in
the controls. Using the haplotype-based General Linear
Model (GLM), statistically signiﬁcant differences were ob-
served between these haplotypes and plasma concentrations
of CRP and albumin (although the absolute differences were
generally small), which is consistent with some of these SNPs
being functional. There were no signiﬁcant differences
between the haplotypes in BMI or plasma concentrations of
apolipoprotein A1, apolipoprotein B, or ﬁbrinogen.
Association with MI Risk
Table 5 displays the associations with MI risk in the ISIS
case-control study for individual SNPs of the LTA gene, after
adjustment for age and sex, when analyzed using co-
dominant, recessive, and dominant genetic models, respec-
tively. Neither the rs909253 nor the rs1041981 SNP for the
LTA gene that was studied by Ozaki et al. [5] was signiﬁcantly
associated with MI risk using any of the genetic models.
Although the most frequent genotype has been used as the
reference category, any group can be compared with any
other since each is displayed with its appropriate conﬁdence
interval (CI) using ‘‘ﬂoated’’ absolute risks (see Materials and
Methods). None of the individual haplotypes for the LTA gene
was associated with MI risk (v
2 test of heterogeneity: v
2
6 ¼
7.97, p ¼ 0.24) (unpublished data).
Comparison with Other Studies
Figure 1 shows the associations of CHD risk with rs909253
or rs1041981 in all previously published studies [5–10] and in
the present ISIS study. Among the six previous studies, three
Table 1. Identity and Base-Pair Position of SNPs for the LTA Gene on Chromosome 6, and Minor Allele Frequencies in Controls in the
ISIS Study
dbSNP
a rsID Base-Pair Position Inter-SNP Distance
b (bp) Gene Location Alternative Name Minor Allele (Frequency)
rs2071590 31647747 0 Upstream — A (0.35)
rs1800683 31648050 303 Upstream 10G/A A (0.36)
rs909253 31648292 242 Intron-1 252A/G G (0.36)
rs746868 31648408 116 Intron-1 — C (0.38)
rs2857713 31648535 127 Exon-2 319C/A C (0.26)
rs3093543 31648736 201 Exon-3 — C (0.06)
rs1041981 31648763 27 Exon-3 804C/A A (0.36)
adbSNP, the Single Nucleotide Polymorphism database (http://www.ncbi.nlm.nih.gov/projects/SNP).
bDistance from the preceding SNP listed above.
bp, base pairs.
DOI: 10.1371/journal.pgen.0020107.t001
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Synopsis
Lymphotoxin-a gene (LTA) encodes a cytokine involved in the
immune system that has been linked with risk of coronary heart
disease (CHD). In one of the first genome-wide association studies, a
Japanese group reported that polymorphisms for the LTA gene were
associated with a 1.8-fold higher risk of CHD. The authors of this
current paper examined associations of several polymorphisms for
the LTA gene with risk of CHD in a case-control study of 6,928 heart
attack survivors and 2,712 unrelated controls in the United Kingdom.
None of the polymorphisms for LTA (including those examined in
the original Japanese study) were associated with CHD risk.
Moreover, a meta-analysis of all published studies found no
significant association of LTA with CHD risk. These findings
emphasize the need for large-scale studies to have sufficient power
to detect associations of genetic variants with CHD risk and the
need for replication of any such associations in independent studies
of even larger size.examined associations with rs909253 [5,6,8] and four exam-
ined associations with rs1041981 [5,7,9,10] (and one study
reported data separately for males and females [8]). For the
ISIS case-control study (without adjustment for age and sex),
the association with rs1041981 is displayed in Figure 1, but
that SNP was in near perfect LD with rs909253 (which had an
odds ratio for MI of 0.99 [99% CI: 0.83–1.17] in a recessive
model and 1.00 [99% CI: 0.89–1.13] in a dominant model: see
Figure 1). After excluding the hypothesis-generating study [5],
the combined odds ratio in a recessive model was 1.07 with a
95% CI of 0.98–1.17 (Figure 1A), and in an autosomal
dominant model, it was 1.09 with a 95% CI of 1.02–1.16
(Figure 1B). For the recessive model, there was no signiﬁcant
heterogeneity between the results of the individual studies
(v
2
6 ¼ 9.9, p ¼ 0.1), although there was a highly signiﬁcant
trend towards the null with increasing study size (v
2
1¼7.0, p¼
0.008). For the dominant model, there was signiﬁcant
heterogeneity between the different study results (v
2
6 ¼
18.0, p ¼ 0.007), but this chieﬂy reﬂected a trend with study
size (v
2
1 ¼ 9.9, p ¼ 0.002) and no signiﬁcant residual
heterogeneity (v
2
5 ¼ 8.1, p ¼ 0.1). Inclusion of the ISIS results
for rs909253 instead of rs1041981 did not change the results
of this meta-analysis materially, with a combined odds ratio
of 1.06 (95% CI: 0.97–1.16) in the recessive model and 1.08
(95% CI: 1.02–1.15) in the dominant model.
Discussion
The ISIS study is the largest genetic association study of MI
risk and polymorphisms in LTA, involving 6,928 MI cases and
2,712 unrelated controls. The recruitment procedure used for
controls in the ISIS case-control study (involving spouses of
siblings and their children: see Materials and Methods) should
have minimised the risk of population admixture between
controls and cases. The seven SNPs studied included three
that had been previously been reported [5], as well as others
identiﬁed by resequencing to be in high LD with each other
(see Materials and Methods), and covered a genomic region of
about 1 kb in the LTA gene. The ISIS case-control study
found no signiﬁcant association of MI risk with any of these
individual SNPs or with any of the six common haplotypes
studied (including those associated with signiﬁcantly higher
plasma concentrations of CRP and albumin).
The present ﬁndings differ from those of the hypothesis-
generating study [5] which reported that, in a recessive model,
the SNPs rs909253 and rs1800683 in the LTA gene were
associated with odds ratios for MI of 1.71 (95% CI: 1.24–2.36)
and 1.78 (95% CI: 1.39–2.27), respectively. That study used a
two-stage design in which 65,671 genetic markers in 13,738
genes were initially screened in 94 MI cases and 658 controls,
and then the 1% of markers that appeared most strongly
associated with MI were re-examined in a further 1,133 MI
cases and 1,006 controls. In that study, a third SNP in LTA
(rs1041981) also appeared to be associated with risk of MI
with an odds ratio of 1.78 (95% CI: 1.39–2.27) [5]. It is possible
that those results represented false-positive results identiﬁed
among the relatively small number of cases. Alternatively, it
may reﬂect an imbalance in the control population which was
selected from several different population sources, since
signiﬁcant departures from Hardy-Weinberg equilibrium
were observed in the genotype distributions in case and
control samples in the Ozaki et al. study [5] (possibly
indicating population stratiﬁcation) [14]. Two further case-
control studies carried out in Japanese populations have
reported conﬂicting results, with one appearing to conﬁrm
an association of the rs909253 SNP with risk of MI [6] and the
other not doing so [8].
In a multicentre European study of 400 trio families, the
Table 3. Pair-Wise Standardised Disequilibrium (D
I) and Correlation (r
2) Coefficients, between Individual SNPs for the LTA Gene
dbSNP
a rsID Polymorphism D
I Pair-wise LD (and r
2 Correlation Coefficients)
rs1800683 rs909253 rs746868 rs2857713 rs3093543 rs1041981
rs2071590 A/G 0.99 (0.30) 1.00 (0.30) 1.00 (0.86) 0.85 (0.13) 1.00 (0.04) 1.00 (0.30)
rs1800683 A/G — 1.00 (0.98) 0.99 (0.34) 0.86 (0.15) 1.00 (0.04) 1.00 (0.99)
rs909253 A/G — — 1.00 (0.34) 0.87 (0.15) 1.00 (0.04) 1.00 (0.99)
rs746868 C/G — — — 0.88 (0.16) 1.00 (0.04) 1.00 (0.34)
rs2857713 C/T — — — — 0.89 (0.15) 0.87 (0.14)
rs3093543 A/C — — — — — 1.00 (0.04)
rs1041981 C/A — — — — — —
adbSNP, the Single Nucleotide Polymorphism database (http://www.ncbi.nlm.nih.gov/projects/SNP).
DOI: 10.1371/journal.pgen.0020107.t003
Table 2. Characteristics of Confirmed Myocardial Infarction
Cases and Controls (Mean [SD] or %)
Characteristic Cases of MI (n ¼ 6,928) Controls (n ¼ 2,712)
Age (y) 54.8 (7.3) 46.2 (9.6)
Percent Male 82.3 44.6
Body mass index (kg/m
2)
a 26.1 (6.6) 24.7 (4.3)
Cigarette smoker (%) 56.7 19.5
Hypertension (%)
a 21.6 11.2
Diabetes mellitus (%)
a 5.5 1.4
Apolipoprotein A1 (g/l)
a 1.14 (0.22) 1.24 (0.20)
Apolipoprotein B (g/l)
a 1.16 (0.29) 0.99 (0.25)
Fibrinogen (g/l)
a 3.71 (0.94) 3.40 (0.84)
CRP (log mg/dl)
a 1.02 (1.95) 0.03 (1.21)
Albumin (g/l)
a 37.8 (3.84) 40.7 (3.50)
aValues were adjusted for age and sex. Data for LTA were available for 6,928 cases and
2,712 controls, whereas plasma biochemistry results were available for between 4,979 and
5,242 cases and for between 2,348 and 2,712 controls.
SD, standard deviation.
DOI: 10.1371/journal.pgen.0020107.t002
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LTA and Risk of Myocardial InfarctionPROCARDIS Consortium reported that rs1041981 was
associated in a recessive model with a 1.96 (95% CI: 1.25–
3.13) higher risk of CHD before age 65 y [7]. In principle, a
study design involving the use of trios should eliminate the
potential risk of population admixture that may occur in
unrelated case-control studies. However, the apparent asso-
ciation in PROCARDIS could still reﬂect the play of chance in
a study involving relatively small numbers of diseased cases. A
subsequent larger, trio family study of 671 UK families
reported no signiﬁcant association of rs1041981 with risk of
MI [10].
An alternative explanation for these apparently discrepant
ﬁndings might be that none of the SNPs in the LTA gene
studied by Ozaki et al. is causally associated with MI, but are
instead in high LD with some other SNP which is present in
higher frequency in Japanese than in populations of Euro-
pean descent [12]. In such circumstances, detection of this
association via the common LTA SNPs would be facilitated in
Japanese populations. There would also be a better chance of
observing it in trio families of European descent [7], since a
sampling strategy based on at least one family member
suffering an MI would inﬂate the frequency of a causal allele
that is otherwise rare in the general population. Lack of SNPs
in the LTA gene that were genotyped in both the European-
descentand Japanese populations in HapMap Phase II [15] did
not allow us to investigate the possibility of differential LD
patterns between the two populations. However, the absence
of an association in a large Japanese population by Yamada et
al. [8] and in another large UK trio family study [10] does not
support this alternative hypothesis. The ISIS study had more
than 90% power to detect a 10% higher risk of MI associated
with rs909253 and rs1041981 SNPs for the LTA gene
(assuming an allele frequency of about 0.35) using co-
dominant or recessive genetic models. The selection of
Table 5. Odds Ratio (95% CI) of MI Associated with SNPs for LTA in ISIS Study (Adjusted for Age and Sex)
dbSNP
a Genotype Frequency Model for Individual SNPs Recessive Model Dominant Model
Cases (%) Controls (%) OR (95% CI) OR (95% CI) OR (95% CI)
rs2071590 GG 44.2 42.7 1.00 (0.92–1.09)
AG 43.9 45.1 0.95 (0.88–1.03) AA vs. GG þ AG GG vs. AG þ AA
AA 11.9 12.2 0.87 (0.75–1.02) 0.89 (0.76–1.05) 0.93 (0.84–1.04)
rs1800683 AA 41.0 40.8 1.00 (0.92–1.09)
AG 45.8 45.6 1.01 (0.93–1.09) GG vs. AG þ AA AA vs. AG þ GG
GG 13.2 13.6 0.91 (0.79–1.06) 1.01 (0.91–1.13) 1.10 (0.94–1.28)
rs909253 AA 41.3 41.1 1.00 (0.92–1.09)
AG 45.6 45.6 1.00 (0.92–1.08) GG vs. AA þ AG AA vs. AG þ GG
GG 13.1 13.3 0.92 (0.79–1.06) 0.92 (0.79–1.07) 0.98 (0.88–1.09)
rs746868 GG 39.7 38.5 1.00 (0.92–1.09)
CG 45.9 47.4 0.93 (0.86–1.01) CC vs. GG þ CG GG vs. CG þ CC
CC 14.4 14.2 0.96 (0.83–1.10) 0.99 (0.85–1.16) 0.94 (0.84–1.05)
rs2857713 TT 54.5 54.8 1.00 (0.93–1.08)
CT 38.5 38.7 1.07 (0.98–1.17) CC vs. TT þ CC TT vs. CT þ CC
CC 7.0 6.5 1.06 (0.86–1.31) 1.03 (0.83–1.28) 1.07 (0.96–1.19)
rs3093543 AA 87.4 87.7 1.00 (0.94–1.06)
AC 12.2 12.0 1.14 (0.98–1.33) CC vs. AC þ AA AA vs. AC þ CC
CC 0.4 0.3 1.83 (0.68–4.97) 1.80 (0.66–4.89) 1.16 (0.98–1.36)
rs1041981 CC 41.4 41.4 1.00 (0.92–1.09)
AC 45.6 45.5 1.01 (0.93–1.09) AA vs. AC þ CC CC vs. AC þ AA
AA 13.0 13.1 0.95 (0.82–1.09) 0.94 (0.80–1.10) 0.99 (0.89–1.11)
adbSNP, the Single Nucleotide Polymorphism database (http://www.ncbi.nlm.nih.gov/projects/SNP).
DOI: 10.1371/journal.pgen.0020107.t005
Table 4. Mean (SE) Values for Selected Characteristics by Haplotypes for the LTA Gene in Controls
LTA Haplotypes Frequency BMI (kg/m
2) ApoA (g/l) ApoB (g/l) Fibrinogen (g/l) CRP (log units) Albumin (g/l)
GAGGTAA 0.35 25.0 (0.2) 1.24 (0.01) 1.00 (0.01) 3.47 (0.03) 0.18 (0.05) 40.0 (0.1)
AGACTAC 0.33 24.8 (0.1) 1.24 (0.01) 0.99 (0.01) 3.41 (0.02) 0.08 (0.04) 40.0 (0.1)
GGAGCAC 0.18 24.9 (0.2) 1.24 (0.01) 0.99 (0.01) 3.44 (0.03) 0.06 (0.05) 38.9 (0.1)
GGAGCCC 0.06 24.5 (0.2) 1.24 (0.01) 1.00 (0.02) 3.41 (0.04) 0.02 (0.07) 39.8 (0.2)
GGACTAC 0.04 24.3 (0.3) 1.24 (0.02) 0.98 (0.02) 3.37 (0.06) 0.11 (0.09) 40.2 (0.3)
GGAGTAC 0.02 24.8 (0.4) 1.23 (0.02) 1.02 (0.03) 3.34 (0.07) 0.16 (0.12) 39.7 (0.4)
All others 0.02 24.5 (0.3) 1.23 (0.02) 1.00 (0.02) 3.48 (0.07) 0.07 (0.12) 40.2 (0.3)
p-Value
a for heterogeneity 0.153 0.129 0.652 0.051 0.004 0.023
aBased on heterogeneity between the six common haplotypes.
ApoA, apolipoprotein A; ApoB, apolipoprotein B.
DOI: 10.1371/journal.pgen.0020107.t004
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of children, together with the very small proportion of
participants of non–European descent in this study would
indicate that the risk of population stratiﬁcation is small.
A major problem in genetic association studies has been
the high proportion of false-positive results suggested by
studies involving relatively small numbers of diseased cases
[11,12]. Attenuation in the strength of the observed associ-
ation in larger studies is consistent with publication bias,
whereby more extreme results are more likely to be published
earlier [16]. The apparent discrepancy between the results of
studies of LTA and CHD risk reinforces the need for studies
involving larger numbers of disease cases, unrelated controls
selected from the same population as the cases, and
genotyping of markers that provide good coverage of the
gene of interest. The ISIS case-control study of nearly 7,000
cases with MI before age 65 y and of family-based controls,
considered in the context of previously reported studies of
this association, provides reliable evidence that these com-
mon polymorphisms for the LTA gene are not strongly
associated with susceptibility to coronary disease. The
present study cannot exclude the possibility of involvement
of other variants near the LTA gene (e.g., in more distal
regulatory regions), which were not considered.
Figure 1. Odds ratio (CI) for Coronary Heart Disease Associated with Genotypes of the LTA Gene in ISIS and Other Studies Using Recessive and
Dominant Models
(A) shows the recessive model and (B) shows the dominant model. Studies are of either the rs909253 SNP (A/G alleles) or the rs1041981 SNP (A/C
alleles). The hypothesis-generating study [5] has been excluded from the combined estimates for all other studies that tested the hypothesised
association. Size of the squares is proportional to the variance of the log odds ratio, and horizontal lines represent the 99% CIs, and the width of the
diamonds represents the 95% CIs. The associations have not been adjusted for age or sex.
DOI: 10.1371/journal.pgen.0020107.g001
PLoS Genetics | www.plosgenetics.org July 2006 | Volume 2 | Issue 7 | e107 0994
LTA and Risk of Myocardial InfarctionMaterials and Methods
Study population. The design of the ISIS case-control study has
been described in detail in previous publications [17,18]. Cases
genotyped for this study were men aged 30–54 y and women aged 30–
64 y, with non-fatal MI conﬁrmed by cardiac enzyme or electro-
cardiographic criteria (or both). Blood was collected on admission to
hospital with their index MI, and a few months later, information was
sought from surviving cases about aspects of their previous lifestyle. A
similar questionnaire was sent to their siblings and children older
than 30 y, and to the spouses of those relatives, with blood sought
from all those who completed a questionnaire. Controls genotyped in
the present study were spouses of their siblings or children (i.e.,
unrelated to the MI cases except by marriage) aged 30–64 y, and with
no history of MI, angina, or other deﬁnite heart disease. Ethnicity was
not recorded, but the family-based recruitment strategy should have
yielded similar distributions among cases and controls (and, based on
other studies conducted by us in these UK hospitals, more than 95%
would be expected to be of European descent [19]). Participants
provided consent to participate in the study, which had research
ethics committee approval.
Laboratory methods. DNA was extracted from frozen buffy coat
samples using a Taqman and ampliﬂuor technique, as previously
described [17,18]. Seven SNPs for LTA (rs2071590, rs1800683,
rs909253, rs746868, rs2857713, rs3093543, and rs1041981) were
selected, including those typed in previous studies, from among all
22 known SNPs for the LTA gene in the National Center for
Biotechnology Information (NCBI) genome assembly 35. Genotyping
using mass spectrometry was carried out at the Centre Nationale de
Genotypage (CNG) in Paris without knowledge of disease status, with
samples from cases and controls distributed within each 384-well
genotyping plate. Internal controls were used to check the
consistency of genotyping between plates, and the reproducibility
of genotyping was assessed by replicate measurements in a random
sample of 250 controls.
Plasma concentrations of apolipoprotein A1 and apolipoprotein B
were measured at the Clinical Trial Service Unit (CTSU) using
Immuno reagents (Vienna, Austria) on Beckman Synchron CX4 and
CX5 auto-analysers (Beckman Coulter UK, Limited, High Wycombe,
England, United Kingdom). Albumin concentrations were also
measured on these auto-analysers using a colorimetric method. A
sample blank absorbance reading was subtracted from the ﬁnal
reaction absorbance to correct any interference due to haemolysis
prior to sample separation [20]. Fibrinogen and high sensitivity CRP
concentrations were measured using Dade-Behring reagents on an
automated Dade-Behring Nephelometer II analyser (Dade-Behring
GmbH, Marburg, Germany). Previous studies had indicated small
changes in measured levels of plasma analytes due to delay in plasma
separation [20] ,so the analyses were adjusted for time from collection
to separation, as well as for date of assay to allow for any slight
analyser drift. The intra-assay coefﬁcients of variation, based on
repeat analyses of control material, were 3%–4% for all plasma
analytes (apolipoprotein A1, apolipoprotein B, albumin, ﬁbrinogen,
and CRP).
Statistical analysis. The genotypic distributions of each SNP were
assessed for HWE in cases and controls separately using an exact chi-
square goodness of ﬁt test. A threshold of p , 0.05 was used to
indicate departure from HWE. Allelic association, or LD, between
SNPs was assessed using the standardised disequilibrium (D
I) [21] and
correlation (r
2) [22] coefﬁcients. The maximum likelihood estimates
of haplotype frequencies and posterior probabilities of pairs of
haplotypes were estimated for each individual with an expectation-
maximization (E-M) algorithm under the HWE assumption using the
Haplostats suite of software in R [23]. Haplotypes with an estimated
frequency .1% were analyzed separately, and the remaining
haplotypes were combined. A weighted kappa score was used to
assess reproducibility of each of the individual SNPs studied. Analysis
of variance was used to assess the associations of haplotypes with
levels of cardiovascular risk factors in controls. Logistic regression
adjusted for age and sex was used to estimate odds ratios for MI of
each SNP and haplotype. Floated absolute risks and CIs were used to
share the variance of the log odds ratios appropriately between the
different genotypes or haplotypes, which allows a CI to be computed
for the reference category and any group to be compared directly
with any other [24,25]. The power calculations for the ISIS case-
control study to detect associations of MI risk with either the
rs909253 or rs10412981 SNP for the LTA gene were estimated using
standard methods [26,27].
Finally, a meta-analysis was conducted of the associations between
rs909253 or rs1041981 (which are in perfect LD in Japanese and
European-descent populations) and the incidence of CHD in the ISIS
study and all other published studies. For the latter studies, odds
ratios for CHD were calculated from the published number of cases
and controls in each of the genotype categories, either assuming an
autosomal dominant model (homozygous and heterozygous vs. wild
type) or recessive model (homozygous vs. heterozygous and wild type).
Since the Ozaki et al. study using a recessive model was the
hypothesis-generating study [5], it was not included in the combined
results for the meta-analysis. The results for all remaining studies
were assessed for heterogeneity and for linear trend by study size
[16,28]. Summary estimates of the odds ratios from all studies were
obtained by combining the separate estimates of the inverse
variance–weighted log odds ratios from each study [29]. To minimise
the risk of false-positive results associated with multiple comparisons,
99% conﬁdence intervals were used for individual studies and 95%
CIs for the sub-totals. All analyses were carried out using SAS version
8.2 (Cary, North Carolina, United States) and R version 1.9.1 (http://
www.r-project.org).
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